LOG IN
SIGN UP
MARKET
AMGN
AMGN
Amgen Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
255.26
+2.21
+0.87%
After Hours: 254.65 -0.61 -0.24% 18:55 05/27 EDT
OPEN
253.50
PREV CLOSE
253.05
HIGH
256.23
LOW
250.92
VOLUME
2.68M
TURNOVER
0
52 WEEK HIGH
258.45
52 WEEK LOW
195.38
MARKET CAP
136.36B
P/E (TTM)
25.13
1D
5D
1M
3M
1Y
5Y
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Zacks · 1d ago
Catalyst watch: GameStop earnings, box office buzz, eyes on Amazon split
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 1d ago
Amgen (AMGN) Up 6.3% Since Last Earnings Report: Can It Continue?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 1d ago
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion.
Benzinga · 1d ago
Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
Investor's Business Daily · 1d ago
Mirati extends losses after KRAS inhibitor data; Stifel says selloff is overdone
Mirati Therapeutics (NASDAQ:MRTX) continued to trade lower in the pre-market after the clinical-stage oncology company updated data for its KRAS inhibitor, adagrasib, while Stifel defended the stock noting that the
Seekingalpha · 1d ago
Amneal, Kashiv's biosimilar therapy to Amgen's Neulasta gets FDA approval
The U.S. Food and Drug Administration (FDA) approved Amneal Pharmaceuticals' (NYSE:AMRX) and Kashiv Biosciences' Fylnetra, a biosimilar to Amgen's (AMGN) Neulasta. Fylnetra (pegfilgrastim-pbbk) is used to treat neutropenia, a condition that occurs
Seekingalpha · 1d ago
BRIEF-New Data Showcases How Amgen Is Advancing All Angles Of Cancer Care Through Innovative Oncology Portfolio And Pipeline At Asco 2022
reuters.com · 2d ago
No Data
Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 30 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
13.33%Strong Buy
20.00%Buy
60.00%Hold
3.33%Under-perform
3.33%Sell
Analyst Price Target
The average AMGN stock price target is 249.34 with a high estimate of 295.00 and a low estimate of 185.00.
Current 255.26
EPS
Actual
Estimate
1.172.343.504.67
Institutional Holdings
Institutions: 2.87K
Institutional Holdings: 459.12M
% Owned: 85.94%
Shares Outstanding: 534.20M
TypeInstitutionsShares
Increased
855
19.67M
New
267
2.87M
Decreased
833
20.82M
Sold Out
121
1.92M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President/General Counsel/Secretary
Jonathan Graham
Executive Vice President/Director of Human Resources
Lori Johnston
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President/Chief Compliance Officer
Nancy Grygiel
Senior Vice President
Rachna Khosla
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Charles Holley
Independent Director
S. Omar Ishrak
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
Robert Williams
No Data
No Data
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.